(Q50577281)

15 March 2018

title

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. (English)

1 reference

15 March 2018

0 references

1 reference

1 reference

Yoshiaki Iwasaki

1

1 reference

15 March 2018

Hiroshi Ikeda

2

1 reference

15 March 2018

Yasuyuki Araki

3

1 reference

15 March 2018

Toshiya Osawa

4

1 reference

15 March 2018

Keiji Kita

5

1 reference

15 March 2018

Masaharu Ando

6

1 reference

15 March 2018

Toshinari Shimoe

7

1 reference

15 March 2018

Kouichi Takaguchi

8

1 reference

15 March 2018

Noriaki Hashimoto

9

1 reference

15 March 2018

Toshitsugu Kobatake

10

1 reference

15 March 2018

Minoru Tomita

11

1 reference

15 March 2018

Mitsuhiko Kawaguchi

12

1 reference

15 March 2018

Haruhiko Kobashi

13

1 reference

15 March 2018

Kohsaku Sakaguchi

14

1 reference

15 March 2018

Yasushi Shiratori

15

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 January 2006

1 reference

15 March 2018

published in

Hepatology

1 reference

15 March 2018

volume

43

1 reference

15 March 2018

page(s)

54-63

1 reference

15 March 2018

issue

1

1 reference

15 March 2018

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

cites work

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

21 January 2018

1 reference

7 January 2021

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002)

1 reference

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

7 January 2021

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

1 reference

7 January 2021

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

1 reference

7 January 2021

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

7 January 2021

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

7 January 2021

Reporting results of cancer treatment

1 reference

7 January 2021

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

7 January 2021

Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups

1 reference

7 January 2021

Importance of age in chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

1 reference

7 January 2021

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

1 reference

7 January 2021

Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice.

1 reference

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

7 January 2021

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

7 January 2021

The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin

1 reference

7 January 2021

The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation

1 reference

7 January 2021

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

7 January 2021

The role of physician extenders in managing patients with chronic hepatitis C.

1 reference

7 January 2021

Epidemiology of hepatitis C in the United States.

1 reference

7 January 2021

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update

1 reference

7 January 2021

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

1 reference

7 January 2021

Epidemiology of hepatitis C virus in japan

1 reference

7 January 2021

Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.

1 reference

7 January 2021

Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20984

1 reference

15 March 2018

PubMed ID

16374855

1 reference

15 March 2018